---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-003704"
form_type: "8-K"
ticker: "ARMP"
cik: "0000921114"
company_name: "Armata Pharmaceuticals, Inc."
filed_at: "2024-03-21T23:59:59+00:00"
generated_at: "2026-06-04T11:09:30.700373+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Armata Pharma Q4 loss $9.6M; secures $35M loan at 14%, matures June 2025

## Summary
- Q4 2023 loss from operations $(9.6)M vs $(10.3)M in Q4 2022; cash $13.5M at Dec 31, 2023.
- Entered $35M credit agreement with Innoviva SO on March 4, 2024; 14% annual rate, matures June 4, 2025.
- Phase 2 diSArm study of AP-SA02 for Staph aureus bacteremia continues dose escalation; Phase 2 Tailwind study of AP-PA02 for NCFB progressing.
- Manufacturing facility advanced; R&D labs completed; five cGMP suites expected H1 2024.

## SEC filing metadata
- accession: 0001558370-24-003704
- form_type: 8-K
- ticker: ARMP
- cik: 0000921114
- company_name: Armata Pharmaceuticals, Inc.
- filed_at: 2024-03-21T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921114/000155837024003704/0001558370-24-003704-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921114/000155837024003704/armp-20240321x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-003704
- JSON: https://secwatch.observer/filing/0001558370-24-003704.json
- Plain text: https://secwatch.observer/filing/0001558370-24-003704.txt

## Key facts
- Earnings Releases
  Armata Pharmaceuticals, Inc. reported the three months and full fiscal year ended December 31, 2023 results: revenue approximately $1.5 million.
  - Period: the three months and full fiscal year ended December 31, 2023
  - Revenue: approximately $1.5 million
  - Result: reported results
  source text: what we are poised to achieve this year and next,” Dr. Birx concluded. Fourth Quarter 2023 Financial Results Grant Revenue. The Company recognized grant revenue of approximately $1.5 million for the three months ended December 31, 2023, which represents Medical Technology Enterprise Consortium’s share of the costs incurred for the Company’s AP-SA02 program for the
  evidence_url: https://www.sec.gov/Archives/edgar/data/921114/000155837024003704/0001558370-24-003704-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.